UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

Journal of clinical oncology, 2019-04, Vol.37 (11), p.912-922

2019

Volltextzugriff (PDF)

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Blood, 2018-02, Vol.131 (8), p.877-887

2018

Volltextzugriff (PDF)

Roxadustat: First Global Approval

Drugs (New York, N.Y.), 2019-04, Vol.79 (5), p.563-572

Dhillon, Sohita

2019

Volltextzugriff (PDF)

Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan

Journal of the American Society of Nephrology, 2020-07, Vol.31 (7), p.1628-1639

2020

Volltextzugriff (PDF)

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Blood, 2018-12, Vol.132 (23), p.2446-2455

2018

Volltextzugriff (PDF)

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Blood, 2018-02, Vol.131 (8), p.888-898

2018

Volltextzugriff (PDF)

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

Clinical journal of the American Society of Nephrology, 2016-06, Vol.11 (6), p.982-991

2016

Volltextzugriff (PDF)

Discovery of Clinical Candidate 1‑{[(2S,3S,4S)‑3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin‑1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design

Journal of medicinal chemistry, 2017-07, Vol.60 (13), p.5521-5542

2017

Volltextzugriff (PDF)

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study

American journal of kidney diseases, 2016-06, Vol.67 (6), p.912-924

2016

Volltextzugriff (PDF)

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

Journal of clinical oncology, 2011-11, Vol.29 (31), p.4189-4198

2011

Volltextzugriff (PDF)

First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor

British journal of cancer, 2020-08, Vol.123 (4), p.525-533

2020

Volltextzugriff (PDF)

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Annals of oncology, 2014-07, Vol.25 (7), p.1328-1333

2014

Volltextzugriff (PDF)

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

Clinical cancer research, 2015-08, Vol.21 (16), p.3705-3715

2015

Volltextzugriff (PDF)

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

Annals of oncology, 2014-07, Vol.25 (7), p.1340-1346

2014

Volltextzugriff (PDF)

Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study

American journal of hematology, 2022-02, Vol.97 (2), p.174-184

2022

Volltextzugriff (PDF)

Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block

British journal of anaesthesia : BJA, 2014-03, Vol.112 (3), p.498-505

2014

Volltextzugriff (PDF)

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy

Annals of oncology, 2014-07, Vol.25 (7), p.1333-1339

2014

Volltextzugriff (PDF)

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

Journal of hepatology, 2013-04, Vol.58 (4), p.655-662

2013

Volltextzugriff (PDF)

Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting

Drugs (New York, N.Y.), 2021-07, Vol.81 (11), p.1331-1342

Shirley, Matt

2021

Volltextzugriff (PDF)

Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy

European journal of cancer (1990), 2024-09, Vol.208, p.114157, Article 114157

2024

Volltextzugriff (PDF)

Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials

JAMA ophthalmology, 2015-07, Vol.133 (7), p.755

2015

Volltextzugriff (PDF)

Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies

British journal of cancer, 2021-08, Vol.125 (5), p.687-698

2021

Volltextzugriff (PDF)

Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial

The American journal of gastroenterology, 2017-05, Vol.112 (5), p.763-774

2017

Volltextzugriff (PDF)

Effects of plant-derived isoquinoline alkaloids on growth performance and intestinal function of broiler chickens under heat stress

Poultry science, 2021-02, Vol.100 (2), p.957-963

2021

Volltextzugriff (PDF)

1 – 25 von 1.814

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.586)
Mit Volltextzugriff
(1.360)

Publikationsform

Artikel
(1.808)
magazinearticle
(6)

Sprache

9 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.385)
Life Sciences & Biomedicine
(1.351)
Humans
(1.220)
Isoquinolines - Administration & Dosage
(1.187)
Male
(1.046)
Female
(792)
Animals
(718)
Adult
(627)
Middle Aged
(584)
Isoquinolines - Pharmacology
(583)
Biological And Medical Sciences
(545)
Medical Sciences
(493)
Pharmacology & Pharmacy
(423)
Aged
(414)
Isoquinolines - Therapeutic Use
(410)
Pharmacology. Drug Treatments
(377)
Rats
(375)
Dose-Response Relationship, Drug
(361)
Isoquinolines - Adverse Effects
(276)
Anesthesiology
(231)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Roxadustat: First Global Approval

Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

Discovery of Clinical Candidate 1‑{[(2S,3S,4S)‑3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin‑1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study

Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting

Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy

Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials

Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies

Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial

Effects of plant-derived isoquinoline alkaloids on growth performance and intestinal function of broiler chickens under heat stress

Suchergebnisse filtern